A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder.
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2016
At a glance
- Drugs Ziprasidone (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 08 May 2014 Results published in the International Clinical Psychopharmacology.
- 14 Mar 2013 Primary endpoint 'Hamilton-Depression-Rating-Scale' has not been met.
- 07 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.